Veracyte global chief commercial off. John Leite sells $160,600 stock

John Leite, Veracyte Inc.'s Global Chief Commercial Officer, traded 4,015 shares of the company's stock on September 21, 2026. The sale occurred as part of a pre-established Rule 10b5-1 trading plan, adopted by Mr. Leite on June 9, 2026. The shares were exchanged at a price of $40.00 per share, generating a total of $160,600. Following the transaction, Mr. Leite retained 124,329 shares of Veracyte common stock.

Since the sale, the stock price has increased, currently trading at $43.36, up from the $40.00 sale price. Veracyte's shares have demonstrated volatility, with a 29% return over the past six months. An InvestingPro analysis suggests that VCYT may be overvalued relative to its Fair Value estimate. Investors can access further ProTips and an in-depth analysis through the platform's Pro Research Report.

Veracyte released positive second-quarter 2026 results, posting adjusted earnings of $0.54 per share and revenue of $150.3 million, exceeding analyst expectations of $0.43 per share and $144.6 million in revenue. The company subsequently raised its full-year revenue outlook. In response to these results, Needham raised its price target for Veracyte to $69 while maintaining a Buy rating.

Freedom Capital also increased its price target to $66, retaining a Buy rating. Conversely, Canaccord lowered its price target to $50, keeping a Hold rating. Additionally, Veracyte announced the acquisition of Convergent Genomics for $150 million, including potential milestone payments of up to $30 million, which includes Convergent's UroAmp assay for non-muscle-invasive bladder cancer patients.

Analysts have responded differently, with Needham reaffirming a Buy rating following the acquisition news.